Literature DB >> 11966757

The in vivo effects of tumour necrosis factor blockade on the early cell mediated immune events and syndrome expression in rat adjuvant arthritis.

K A Bush1, B W Kirkham, J S Walker.   

Abstract

Anti-TNF therapy is effective in rheumatoid arthritis (RA); however, its mechanisms of action are incompletely understood. T cell-driven mechanisms are thought to play an important role in RA and the effects of TNF blockade on these mechanisms are unclear. Adjuvant arthritis (AA) is a T cell dependent model of inflammatory arthritis. The aims of this study were to investigate the effects of TNF blockade on in vivo T cell cytokine expression and to clarify the role of TNF in the inguinal lymph nodes (ILN) in early arthritis. AA was induced in male DA rats. Rats received either 3 mg/kg or 10 mg/kg PEG sTNF-RI at days 0, 2 and 4 postinduction or 10 mg/kg anti-TNF antibody on day of arthritis induction. Control rats received either saline or normal sheep serum. Paw volume was assessed every 3-4 days. Rats were sacrificed on days 0, 6, 13 and 21 postinduction. Ankles were removed for quantitative radiology and histology. Synovium and ILN were removed for cell culture and to determine mRNA expression of cytokines using semiquantitative RT-PCR. TNF and IFN-gamma protein production was measured using a bioassay and an ELISA. TNF blockade did not suppress mRNA expression of T cell cytokines in the ILN of rats in the early phase of AA, suggesting ongoing T cell activity. TNF protein production by ILN cells in culture was reduced in PEG sTNF-RI treated rats, although mRNA expression was increased in the ILN prior to culture. Early administration of PEG sTNF-RI did not attenuate AA, in contrast to an anti-TNF antibody, which suppressed disease. A shorter half-life for the PEG sTNF-RI compared with the anti-TNF antibody or the development of anti-PEG sTNF-RI antibodies may account for these results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11966757      PMCID: PMC1906318          DOI: 10.1046/j.1365-2249.2002.01742.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Intraarticular variability of synovial membrane histology, immunohistology, and cytokine mRNA expression in patients with rheumatoid arthritis.

Authors:  B Kirkham; I Portek; C S Lee; B Stavros; A Lenarczyk; M Lassere; J Edmonds
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

2.  Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171.

Authors:  W Binder; C Scott; J S Walker
Journal:  Eur J Neurosci       Date:  1999-06       Impact factor: 3.386

3.  Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene.

Authors:  C H Le; A G Nicolson; A Morales; K L Sewell
Journal:  Arthritis Rheum       Date:  1997-09

4.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.

Authors:  Y S Lin; C Nguyen; J L Mendoza; E Escandon; D Fei; Y G Meng; N B Modi
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

5.  Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy.

Authors:  J McComb; T Gould; E Chlipala; G Sennelo; J Frazier; G Kieft; J Seely; C K Edwards; A Bendele
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

Review 6.  Inhibitors of tumor necrosis factor for rheumatoid arthritis.

Authors:  L W Moreland
Journal:  J Rheumatol Suppl       Date:  1999-05

7.  Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice.

Authors:  L Mori; S Iselin; G De Libero; W Lesslauer
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

8.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

Authors:  A P Cope; M Londei; N R Chu; S B Cohen; M J Elliott; F M Brennan; R N Maini; M Feldmann
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

9.  In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.

Authors:  H M Lorenz; C Antoni; T Valerius; R Repp; M Grünke; N Schwerdtner; H Nüsslein; J Woody; J R Kalden; B Manger
Journal:  J Immunol       Date:  1996-02-15       Impact factor: 5.422

10.  Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy.

Authors:  R O Williams; C Mauri; L J Mason; L Marinova-Mutafchieva; S E Ross; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1998-10
View more
  6 in total

1.  Protective effects of indomethacin and cyclophosphamide but not of infliximab on liver metabolic changes caused by adjuvant-induced arthritis.

Authors:  Maria Angélica Raffaini Covas Pereira da Silva; Ciomar Aparecida Bersani-Amado; Emy Luiza Ishii-Iwamoto; Lívia Bracht; Silvana Martins Caparroz-Assef
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

Review 2.  Regulation of autoimmune inflammation by pro-inflammatory cytokines.

Authors:  Eugene Y Kim; Kamal D Moudgil
Journal:  Immunol Lett       Date:  2008-08-09       Impact factor: 3.685

3.  Quantitative dynamic models of arthritis progression in the rat.

Authors:  Justin C Earp; Debra C Dubois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2008-08-30       Impact factor: 4.200

4.  Effect of Uncaria tomentosa extract on purinergic enzyme activities in lymphocytes of rats submitted to experimental adjuvant arthritis model.

Authors:  Lívia G Castilhos; João F P Rezer; Jader B Ruchel; Maria Luiza Thorstenberg; Jeandre A dos S Jaques; Josiane B Schlemmer; Pedro H Doleski; Mateus F Rossato; Mariane A da Silva; Emerson André Casalli; Ritiel Corrêa da Cruz; Juliano Ferreira; Margareth L Athayde; Jamile F Gonçalves; Daniela B R Leal
Journal:  BMC Complement Altern Med       Date:  2015-06-20       Impact factor: 3.659

5.  A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats.

Authors:  Fabrizio Vincenzi; Melissa Padovan; Martina Targa; Carmen Corciulo; Sarah Giacuzzo; Stefania Merighi; Stefania Gessi; Marcello Govoni; Pier Andrea Borea; Katia Varani
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

6.  Exogenous tumour necrosis factor alpha induces suppression of autoimmune arthritis.

Authors:  E Y Kim; H H Chi; R Rajaiah; K D Moudgil
Journal:  Arthritis Res Ther       Date:  2008-04-01       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.